Snowden Capital Advisors LLC Nymox Pharmaceutical Corp Transaction History

Snowden Capital Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.21 - $2.0 $816 - $1,350	-675 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.95 - $2.1 $641 - $1,417	675 New	675 $0
Q1 2020 Jan 08, 2024	SELL	$1.69 - $3.88 $114,075 - $261,900	-67,500 Closed	0 $0
Q4 2019 Jan 08, 2024	BUY	$1.73 - $2.42 $116,775 - $163,350	67,500 New	67,500 $1.49 Million
Q3 2019 Jan 08, 2024	SELL	$1.41 - $2.12 $141,000 - $212,000	-100,000 Closed	0 $0
Q2 2019 Jan 08, 2024	BUY	$1.33 - $2.12 $133,000 - $212,000	100,000 New	100,000 $979,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Snowden Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Snowden Capital Advisors LLC with notifications on news.